Switglim mv
Each uncoated bilayered tablet contains:glimepiride + voglibose ip + metformin hydrochloride ip (as sustained release)
1 x 15 tab/ strip
Glimepiride stimulates insulin release from the pancreas. Metformin lowers glucose production by the liver and improves insulin sensitivity. Voglibose slows carbohydrate digestion, reducing blood sugar spikes after meals. Together, they effectively control blood glucose by increasing insulin, decreasing sugar production, and slowing sugar absorption
As prescribed by physician/ respective specialist or rmp
Common side effects of include low blood sugar (hypoglyceamia), nausea, diarrhoea, abdominal pain, constipation, and changes in taste
Glimepiride stimulates insulin secretion by binding to sulfonylurea receptors (sur1) on pancreatic β-cells, leading to closure of k⁺-atp channels and enhanced insulin release.metformin decreases hepatic glucose production (gluconeogenesis) and improves peripheral insulin sensitivity, enhancing glucose uptake in skeletal muscle and adipose tissue. Voglibose inhibits intestinal alpha-glucosidase enzymes, delaying carbohydrate digestion and absorption, thereby controlling postprandial hyperglycemia
